华兰生物(002007.SZ)：参股公司收到药物临床试验批准通知书

Core Viewpoint - Hualan Biological Engineering Co., Ltd. announced that its subsidiary, Hualan Ankang Biopharmaceutical Co., Ltd., received approval for clinical trials of its biosimilar drug, Pembrolizumab injection, marking a significant step in expanding its product pipeline and optimizing product structure [1][2]. Group 1 - Hualan Ankang has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing it to officially conduct clinical research on Pembrolizumab injection [1]. - Pembrolizumab is a humanized monoclonal antibody targeting the PD-1 immune checkpoint, which plays a crucial role in tumor immune evasion by inhibiting T cell activity [1]. - The original product, Keytruda, developed by Merck, is one of the first PD-1 inhibitors approved globally for various significant cancer indications, including non-small cell lung cancer and melanoma [1]. Group 2 - The approval of clinical trials for Pembrolizumab injection signifies the drug's potential to further validate its safety and efficacy, laying the groundwork for future registration and market launch [2]. - Currently, there are no similar drugs approved for marketing in China, highlighting the competitive advantage for Hualan Ankang in the biosimilar market [2].